CD19+ Diffuse Large B-cell Lymphomas
1 clinical trials · Condition
◉ Watch CD19+ Diffuse Large B-cell Lymphomas
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas (NCT02650999) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
Track CD19+ Diffuse Large B-cell Lymphomas automatically
Every clearance here is in the API, with alerts when new ones post.